Advertisement
Australia markets closed

  • ALL ORDS

    7,898.90
    +37.90 (+0.48%)
     

  • AUD/USD

    0.6441
    +0.0005 (+0.07%)
     

  • ASX 200

    7,642.10
    +36.50 (+0.48%)
     

  • OIL

    82.17
    -0.52 (-0.63%)
     

  • GOLD

    2,400.50
    +12.10 (+0.51%)
     

  • Bitcoin AUD

    96,873.91
    -598.67 (-0.61%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

Autolus Limited
·1-min read

Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT

LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. Note this is a change to the timing announced previously.

New timing of investor call

Management will host a conference call and webcast on Monday, December 13, 2021, at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus’ website.

ADVERTISEMENT

Conference Dial in:

  • United States and Canada (866) 679-5407

  • International (409) 217-8320

  • Conference ID 31044873

Replay:
A replay will be available for one week following the call

  • United States and Canada (855) 859-2056

  • International (404) 537-3406

  • Conference ID 31044873

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Business Strategy and Planning
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com